NCT02729207终止2 期
A Phase II, Randomized, Double-blind, Placebo Controlled, Proof of Concept Study to Investigate the Safety and Efficacy of the Esflurbiprofen Hydrogel Patch in Treatment of Acute Pain Associated With Ankle Injury
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Sum of intensity of pain difference after 48hr treatment (SPID48h)
研究概览
简要总结
The safety and the efficacy of the Esflurbiprofen Hydrogel Patch will be assessed in comparing with placebo in the treatment of acute pain due to ankle sprain
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be a male or female aged 18 to 65 years, inclusive.
- •Subject must have a diagnosis of uncomplicated acute minor ankle sprain of Grade I or II as defined by the AAOS criteria.
- •Ankle sprain must have occurred <48 hours prior to Screening.
- •Subject must have a baseline self-evaluated pain score of >50 mm on a 100 mm VAS while bearing weight on the affected ankle.
- •Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of the study product.
- •Subject must be willing to refrain from using any other pain medication (other than allowed rescue medication) during their participation.
排除标准
- •Subject is a pregnant, breastfeeding, or lactating female.
- •Subject has an acute ankle sprain of Grade III as defined by AAOS criteria.
- •Subject has an ankle fracture as confirmed by X-ray.
- •Ankle sprain requires surgical treatment.
- •Subject has experienced recurrent sprains (≥3 sprains of the same joint) or has sprained the affected joint within the last 12 months.
- •Subject has taken analgesics other than NSAID(s) or acetaminophen for any purpose within 7 days of Screening.
- •Subject has taken flurbiprofen or naproxen within 24 hours of Screening.
- •Ankle sprain is treated prior to Screening by ultrasound, physical therapy, or acupuncture.
- •Subject has used immunomodulators or immunosuppressive therapies (e.g., interferon, oral or parenteral corticosteroids, and cytotoxic drugs) within 4 weeks prior to randomization.
- •Subject has used any medicated topical agents (e.g., medicated creams or lotions) on the affected ankle within 7 days prior to Screening.
- •Subject is currently using any other medications that, in the opinion of the Investigator, may exacerbate or mask the anticipated side effects of NSAIDs or interfere with the Investigator's ability to monitor for them (e.g., blood thinners or proton-pump inhibitors).
- •Subject has non-intact or damaged skin in the area to be treated (e.g., eczema, psoriasis, exudative dermatitis, infected lesion, burn, or wound).
- •Subject has a history of ulcers, GI bleeding, hypertension, edema, heart failure, or CV disease.
- •Subject has asthma (except childhood asthma), urticaria, angioedema, or bronchospasm.
- •a.A subject is eligible for the study if they have had no symptoms of these conditions that required medication in the 5 years prior to Screening.
- •Subject has a history of any chronic pain disorder.
- •Subject has coagulation defects.
- •Subject has a history of severe cardiac, renal, or hepatic impairment within 12 months prior to Screening that, in the opinion of the Investigator, would interfere with the outcome of the study.
- •Subject has a severe systemic disease (e.g., cancer or severe acute infection).
- •Subject has a known allergy or hypersensitivity to flurbiprofen, aspirin, other NSAID(s), or any excipient in the IP.
- •Subject has any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.
- •Subject has a history of uncontrolled chronic or acute concomitant disease that, in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results.
- •Subject has applied ice or compression to the affected ankle within 2 hours prior to Screening.
- •Subject has a bilateral ankle injury.
- •Subject has an ipsilateral knee injury. In the opinion of the Investigator, are unsuitable for inclusion in the study.
研究组 & 干预措施
Esflurbiprofen 1.5% Hydrogel Patch
Active Comparator
One patch per 24hr for 7 days
干预措施: Esflurbiprofen Hydrogel Patch (Drug)
Placebo comparator
Placebo Comparator
Placebo One patch per 24hr for 7 days
干预措施: Esflurbiprofen Hydrogel Patch (Drug)
结局指标
主要结局
Sum of intensity of pain difference after 48hr treatment (SPID48h)
时间窗: 48hr after treatment starting
SPID48h will be compared between EFHP and placebo.
次要结局
- SPID24h(24hr after treatment starting)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase 2b Diabetic Kidney Disease StudyDiabetic Kidney DiseaseNCT04170543AstraZeneca609
Unknown
2 期
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 InfectionCOVID-19 DiseaseNCT04969172Eli Sprecher, MD155
招募中
2 期
Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in ChinaCOVID-19NCT05682599Shanghai Henlius Biotech300
尚未招募
2 期
Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)Acute Ischemic StrokeNCT06040476StemCyte, Inc.39
已完成
2 期
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GAAge-related Macular DegenerationNCT03891875Stealth BioTherapeutics Inc.176